Classification of Cirrhosis Following Hepatitis

Hepatic cirrhosis following chronic hepatitis—commonly referred to as post-hepatitis cirrhosis—is a progressive, fibrotic liver disorder that develops after prolonged inflammation and hepatocyte injury, most frequently due to chronic viral hepatitis B or C infection. Clinically, this condition is classified into several morphological and functional subtypes based on histopathological architecture, disease tempo, and clinical behavior.

The primary classification system distinguishes post-hepatitis cirrhosis into three major types: micronodular, macronodular, and mixed (or transitional) cirrhosis. Micronodular cirrhosis is characterized by uniformly small regenerative nodules—typically less than 3 mm in diameter—surrounded by broad, fibrous septa. This pattern often reflects long-standing, slowly progressive disease, such as in chronic hepatitis B with sustained viral replication and gradual fibrogenesis.

In contrast, macronodular cirrhosis features larger, irregular regenerative nodules exceeding 3 mm, sometimes reaching several centimeters. These nodules arise against a background of heterogeneous fibrosis and are commonly associated with episodes of acute-on-chronic liver injury—such as superimposed hepatitis flares or alcohol-related insults—in patients with preexisting chronic hepatitis. Macronodular architecture correlates with more variable clinical courses and carries an elevated risk of hepatocellular carcinoma.

Mixed cirrhosis combines features of both micronodular and macronodular patterns within the same liver specimen, suggesting dynamic evolution—often reflecting transitions from early, uniform fibrosis to later-stage architectural remodeling. This subtype frequently occurs in patients with fluctuating disease activity, including those undergoing antiviral therapy or experiencing intermittent viral suppression and reactivation.

Additional subclassifications consider etiologic drivers, disease duration, and functional reserve—such as compensated versus decompensated status—and increasingly incorporate non-invasive biomarkers (e.g., liver stiffness measurement via elastography) and serum fibrosis indices (e.g., APRI, FIB-4) to refine prognostic stratification. Accurate subtyping informs surveillance strategies, timing of liver transplantation evaluation, and personalized management of complications including portal hypertension, variceal bleeding, and hepatic encephalopathy.